GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080

You Might Also Like...

Key Points About GeoVax

Blogs: GOVX

Recent News Releases

GeoVax Labs, Inc. (GOVX-OTC)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology against infectious diseases and cancer. The Company’s patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is focused on developing vaccines against hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), Zika virus (ZIKV), malaria, and human immunodeficiency virus (HIV). The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). Furthermore, GeoVax is collaborating with Emory University to develop a therapeutic vaccine for human papillomavirus (HPV) infection, with a specific focus on head and neck cancer (HNC). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, with plans to expand its pipeline.

* The Corporate Snapshot was last updated on April 1, 2019.


Latest Research

Cover Image Update 05-28-19




Download Update




Past Research

Cover Image Update 04-01-19

Download Update


Cover Image Update 11-14-18

 Download Update


Cover Image Update 08-14-18_jpg

Download Update



Download Update



Download Update



Download GeoVax Report


Key Points About GeoVax

Blogs: GOVX